Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II)

Phase 3

• Conditions: Malaria

• Registration Number: PACTR201907479787308
• Lead Sponsor: Colorado State University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-29
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 4700

Inclusion Criteria

Residence in selected study village
Able to understand the information and willing to give consent or assent (age 12-18) and parent/guardian consent if study participant age is < 18 years of age.

Exclusion Criteria

Residence outside of the study village
Height < 90 cm (*note: if subject becomes =90cm over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)
Current treatment with SP+AQ as part of SMC (restricted to children 3-48 months old) (*note: if subject discontinuous SP+AQ treatment because they become older than 48 months over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)
Permanent disability or serious medical illness that prevents or impedes study participation and/or comprehension
Pregnancy (screened for in women of child-bearing age [ages 15-45] using a pregnancy urine rapid test [e.g. SD Bioline hCG] the week prior to each MDA)
Breast feeding if infant is within 1 week of birth Known allergy to ivermectin
Possibility of Loa loa infection as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria, and Sudan.
Enrolled in any other active clinical trials

Study & Design

• Study Type: Interventional
• Study Design: Not specified